Log in

NASDAQ:PETXAratana Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$4.92
MA: $4.92
$4.92
52-Week Range N/A
VolumeN/A
Average Volume1.03 million shs
Market Capitalization$241.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. It is also developing NOCITA, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-016, allogeneic adipose-derived stem cells for dogs; and AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications. In addition, the company develops AT-008, a therapeutic candidate for treating canine lymphoma in dogs; and other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; Pacira Pharmaceuticals, Inc. to develop and commercialization of licensed animal health products for NOCITA; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
Read More
Aratana Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.93 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PETX
CUSIPN/A
Phone913-353-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.41 million
Book Value$2.07 per share

Profitability

Net Income$-14,720,000.00

Miscellaneous

Employees83
Market Cap$241.08 million
Next Earnings DateN/A
OptionableOptionable

Receive PETX News and Ratings via Email

Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter.

Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics Inc (NASDAQ:PETX) issued its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. The biopharmaceutical company had revenue of $21.56 million for the quarter, compared to the consensus estimate of $5.70 million. Aratana Therapeutics had a negative net margin of 33.47% and a negative return on equity of 12.99%. View Aratana Therapeutics' earnings history.

Has Aratana Therapeutics been receiving favorable news coverage?

Media coverage about PETX stock has been trending somewhat negative on Sunday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aratana Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutAratana Therapeutics.

Who are some of Aratana Therapeutics' key competitors?

What other stocks do shareholders of Aratana Therapeutics own?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the following people:
  • Mr. Craig A. Tooman, Pres, CEO & Board Director (Age 53)
  • Ms. Rhonda L. Hellums, CFO & Treasurer (Age 47)
  • Mr. John C. Ayres J.D., VP of Corp. Devel. and Admin., Gen. Counsel & Sec. (Age 40)
  • Mr. Brent A. Standridge, Consultant (Age 61)
  • Ms. Rachel Reiff, Head of Corp. Communications

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $0.00 and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 83 workers across the globe.

What is Aratana Therapeutics' official website?

The official website for Aratana Therapeutics is www.aratana.com.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]

This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.